Signal Genetics | GenomeWeb

Signal Genetics

Revenue from tests billed for clinical patients rose 93 percent year over year, the firm said, though its net loss widened to $2.8 million.

The company said sales of its MyPRS test for myeloma risk increased during the quarter, but full-year 2015 revenues fell because of increased R&D costs.

The study will evaluate Signal's MyPRS test for stratifying patients at risk of developing symptomatic multiple myeloma.

The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.


The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.

The company's revenues fell as test orders from its primary customer dropped 22 percent, a trend it said is expected to continue. 

The firm's MyPRS multiple myeloma prognostic assay will be available to 22 million patients across the US covered by America's Choice Provider Network.

The company said that a decrease in tests billed to UAMS was the main driver for the revenue decrease. 

The firm's Little Rock, Ark., laboratory has passed inspection by the College of American Pathologists.

The firm also said it had a net loss of $7.9 million, or $3.50 per share, in 2014, compared to a net loss of $2.4 million, or $12.23 per share, in 2013.


Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.